RADX
Radiopharm·NASDAQ
--
--(--)
--
--(--)
RADX fundamentals
During H1 2026, Radiopharm (RADX) reported revenue of 924.02K, a YoY change of 7.97%. Net income was -18.84M, a YoY change of -55.04%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | H1,2026 | TTM |
|---|
Start Date | Feb 11, 2021 | Jul 1, 2021 | Jul 1, 2021 | Jul 1, 2022 | Jul 1, 2022 | Jul 1, 2023 | Jul 1, 2023 | Jul 1, 2024 | Jul 1, 2024 | Jul 1, 2025 | -- |
End Date | Jun 30, 2021 | Dec 31, 2021 | Jun 30, 2022 | Dec 31, 2022 | Jun 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | -- |
Revenue | -- -- | -- -- | -- -- | 198.95K -- | 194.80K -- | -- -- | 199.79K +2.56% | 855.79K -- | 2.39M +1095.35% | 924.02K +7.97% | 2.46M -- |
Sales and Services Revenue | -- -- | -- -- | 0 -- | 198.95K -- | 194.80K -- | 0 -100.00% | 199.79K +2.56% | 855.79K -- | 2.39M +1095.35% | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | 998.77K -- | 2.36M -- | 855.27K -14.37% | 2.22M -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | 998.77K -- | 2.36M -- | -- -- | -- -- |
Gross Profit | -- -- | -- -- | -- -- | 198.95K -- | 194.80K -- | 0 -100.00% | 199.79K +2.56% | -142.98K -- | 25.82K -87.08% | -- -- | -- -- |
Other Operating Income | -- -- | -- -- | 0 -- | -- -- | 3.87M -- | 2.78M -- | 78.09K -97.98% | 651.72K -76.52% | 6.51M +8237.31% | -- -- | -- -- |
Operating Expenses | 363.70K -- | 6.44M -- | 13.76M +3682.90% | 8.37M +29.99% | 27.04M +96.55% | 15.79M +88.63% | 31.80M +17.60% | 12.76M -19.22% | 31.63M -0.54% | -- -- | -- -- |
Selling, General and Administrative Expenses | 363.37K -- | 4.02M -- | 8.59M +2263.65% | 4.66M +16.07% | 10.17M +18.45% | 5.48M +17.59% | 10.47M +2.90% | 4.35M -20.66% | 10.87M +3.80% | -- -- | -- -- |
General and Administrative Expenses | -- -- | -- -- | 5.27M -- | -- -- | -- -- | 4.47M -- | -- -- | 3.92M -12.21% | -- -- | -- -- | -- -- |
Research and Development Expenses | -- -- | 1.99M -- | 5.17M -- | 5.75M +189.57% | 15.08M +191.70% | 10.31M +79.16% | 15.41M +2.22% | 8.41M -18.46% | 18.09M +17.33% | -- -- | -- -- |
Other Operating Expenses | 327.58 -- | 435.90K -- | -- -- | -2.05M -569.28% | 1.79M -- | -- -- | 5.92M +230.78% | -- -- | 2.68M -54.78% | -- -- | -- -- |
Operating Income | -363.70K -- | -6.44M -- | -13.76M -3682.90% | -8.17M -26.90% | -22.98M -67.02% | -13.02M -59.27% | -31.52M -37.18% | -12.25M +5.91% | -25.09M +20.40% | -- -- | -- -- |
Non-Operating Income (Loss) | -- -- | -6.18M -- | -7.22M -- | -339.75K +94.51% | -57.36K +99.21% | -3.86M -1037.57% | -429.26K -648.32% | 162.93K +104.22% | -42.92K +90.00% | -- -- | -- -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -3.93M -- | -- -- | -285.58K +92.74% | -- -- | -- -- | -- -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -766.12K -- | -- -- | -- -- | 91.45K -- | -- -- | 448.34K +390.27% | -- -- | -- -- | -- -- |
Net Interest Expense | -- -- | 6.18M -- | 6.45M -- | 339.75K -94.51% | 57.36K -99.11% | 25.25K -92.57% | 429.26K +648.32% | -176.27 -100.70% | 42.92K -90.00% | -- -- | -- -- |
Interest Expense | -- -- | 6.18M -- | 6.46M -- | 339.75K -94.51% | 57.36K -99.11% | -- -- | 429.26K +648.32% | -- -- | 42.92K -90.00% | -- -- | -- -- |
Interest Income | -- -- | -- -- | 6.10K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Pretax Income From Continuing Operations | -363.70K -- | -12.63M -- | -20.97M -5666.96% | -8.51M +32.57% | -23.04M -9.83% | -16.88M -98.31% | -31.95M -38.70% | -12.09M +28.41% | -25.13M +21.33% | -18.75M -55.10% | -31.79M -- |
Income Tax Expense | -- -- | -- -- | 30.66K -- | 27.93K -- | 25.32K -17.40% | 21.32K -23.68% | 64.34K +154.09% | 62.45K +192.97% | 67.89K +5.52% | 89.57K +43.42% | 95.01K -- |
Current Income Tax | -- -- | -- -- | 30.66K -- | -- -- | 25.32K -17.40% | -- -- | 64.34K +154.09% | -- -- | 67.89K +5.52% | -- -- | -- -- |
Net Income | -363.70K -- | -12.63M -- | -21.01M -5675.39% | -8.54M +32.35% | -23.06M -9.79% | -16.90M -97.91% | -32.02M -38.83% | -12.15M +28.13% | -25.20M +21.28% | -18.84M -55.04% | -31.89M -- |
Net Income Attributable to Minority Interests | -- -- | -- -- | -- -- | -- -- | -- -- | -741.83K -- | -- -- | -567.51K +23.50% | -- -- | -- -- | -- -- |
Net Income Attributable to Owners of the Company | -363.70K -- | -12.63M -- | -21.01M -5675.39% | -8.54M +32.35% | -23.06M -9.79% | -16.16M -89.22% | -32.02M -38.83% | -11.58M +28.34% | -25.20M +21.28% | -- -- | -- -- |
Net Income Attributable to Common Stockholders | -363.70K -- | -12.63M -- | -21.01M -5675.39% | -8.54M +32.35% | -23.06M -9.79% | -16.16M -89.22% | -32.02M -38.83% | -11.58M +28.34% | -25.20M +21.28% | -- -- | -- -- |
Other Comprehensive Income | -- -- | -9.08K -- | -13.15K -- | -619.94 +93.18% | -485.23K -3590.21% | 6.09K +1081.56% | 135.51K +127.93% | 232.52K +3721.09% | 305.01K +125.08% | 274.02K +17.85% | 346.52K -- |
Total Comprehensive Income | -363.70K -- | -12.63M -- | -21.02M -5679.01% | -8.54M +32.39% | -23.55M -12.03% | -16.90M -97.82% | -31.88M -35.39% | -11.92M +29.48% | -24.90M +21.90% | -18.56M -55.76% | -31.54M -- |
Total Comprehensive Income Attributable to Minority Interests | -- -- | -- -- | 0 -- | -49.53K -- | -108.29K -- | -741.83K -1397.82% | -1.31M -1111.07% | -567.51K +23.50% | -1.08M +17.84% | -- -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -363.70K -- | -12.63M -- | -20.99M -5671.78% | -8.49M +32.78% | -23.44M -11.65% | -16.16M -90.24% | -30.57M -30.42% | -11.35M +29.76% | -23.82M +22.08% | -- -- | -- -- |
Basic EPS | -363.7 -- | -0.12 -- | -0.12 +99.97% | -0.03 +75.00% | -0.08 +33.33% | -0.05 -66.67% | -0.08 -- | -0.01 +80.00% | -0.01 +87.50% | -0.01 -- | -0.01 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -0.12 -- | -- -- | -0.08 +33.33% | -0.05 -- | -0.08 -- | -0.01 +80.00% | -- -- | -- -- | -- -- |
Diluted EPS | -363.7 -- | -0.12 -- | -0.12 +99.97% | -0.03 +75.00% | -0.08 +33.33% | -0.05 -66.67% | -0.08 -- | -0.01 +80.00% | -0.01 +87.50% | -0.01 -- | -0.01 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -0.12 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
You can ask Aime
What guidance did Radiopharm's management provide for the next earnings period?What is Radiopharm's gross profit margin?Did Radiopharm beat or miss consensus estimates last quarter?What factors drove the changes in Radiopharm's revenue and profit?What does Radiopharm do and what are its main business segments?What were the key takeaways from Radiopharm's earnings call?What is the market's earnings forecast for Radiopharm next quarter?What is the revenue and EPS growth rate for Radiopharm year over year?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
